Shalby Ltd
Shalby Ltd operates in the healthcare sector, providing healthcare services and equipment, with a primary focus on pharmaceuticals.
Business. Shalby Ltd (SHAY.NS) is a healthcare services and equipment company primarily engaged in pharmaceuticals and healthcare facilities and services. The firm operates on a service-revenue model within the broader healthcare sector. Shalby Ltd is headquartered in India and is listed on the National Stock Exchange of India. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Shalby Ltd (SHAY.NS) is a healthcare services and equipment company primarily engaged in pharmaceuticals and healthcare facilities and services. The firm operates on a service-revenue model within the broader healthcare sector. Shalby Ltd is headquartered in India and is listed on the National Stock Exchange of India. Specific details regarding operating segments and geographic revenue mix are not available.
Shalby Ltd's capital structure is characterized by a debt-to-equity ratio of 0.48, indicating a relatively conservative leverage position compared to the industry median. The company's liquidity is assessed as medium, with a current ratio of 1.45, suggesting it can cover its short-term obligations but with limited buffer. However, the company's operating cash flow is negative at -43.42 million INR, and free cash flow is also negative at -16.73 million INR, signaling potential liquidity constraints in the near term.
Profitability metrics for Shalby Ltd show a return on equity (ROE) of 0.63% and a return on assets (ROA) of 0.37%, both of which are below the industry median for healthcare providers. The company's net income of 62.23 million INR is modest relative to its revenue of 10.87 billion INR, indicating low profitability. Gross profit of 4.52 billion INR represents 41.7% of revenue, which is in line with the industry average, but the operating margin of 6.4% is below the median for the sector.
Geographically, Shalby Ltd's revenue is concentrated in India, with no disclosed international operations. The company's business is primarily driven by its domestic healthcare services and pharmaceuticals segments. There is no detailed breakdown of revenue by business segment in the latest financial data, but the company's primary activity is in pharmaceuticals.
The company's growth trajectory is mixed. Revenue for the latest period is reported at 10.87 billion INR, but there is no year-over-year growth data provided. Analysts have assigned a mean price target of 192.00 INR, with a single "buy" recommendation and no "strong buy" or "hold" ratings. This suggests limited optimism about the company's near-term growth potential. The company's capital expenditure of -714.46 million INR indicates a significant investment in infrastructure or expansion, which could support future growth if it translates into higher revenue and profitability.
Risk factors for Shalby Ltd include medium liquidity risk, as the company has negative net cash after subtracting total debt. The dilution risk is assessed as low, with no significant dilution expected in the near term. The company's debt load is manageable, with long-term debt of 4.76 billion INR, but the negative operating and free cash flows could pose challenges in maintaining debt serviceability. The risk assessment also highlights the need for improved cash flow generation to support ongoing operations and reduce reliance on external financing.
Recent events and disclosures for Shalby Ltd include the latest financial results, which show a decline in operating and free cash flows. There are no recent filings or transcripts indicating major strategic shifts or regulatory changes. The company's financial performance and capital structure suggest a need for operational improvements to enhance profitability and cash flow generation.
- Shalby Ltd has a conservative debt-to-equity ratio of 0.48, but its liquidity is assessed as medium due to negative operating and free cash flows.
- The company's profitability is weak, with ROE and ROA below the industry median, and a low operating margin of 6.4%.
- Revenue is concentrated in India, with no disclosed international operations, and the company's primary activity is in pharmaceuticals.
- Analysts have assigned a mean price target of 192.00 INR, with only one "buy" recommendation, indicating limited near-term growth expectations.
- The company's capital expenditure of -714.46 million INR suggests ongoing investment in infrastructure or expansion, which could support future growth if it translates into higher revenue and profitability.
- Risk factors include medium liquidity risk and the need for improved cash flow generation to support ongoing operations and reduce reliance on external financing.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,80 |
| Revenue | —no estimate | —no estimate | 11,3B INR |
| Operating income | —no estimate | —no estimate | 738,0M INR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Shalby Ltd Market data — financials · 2026-05-29
- Shalby Ltd Market data — analyst estimates · 2026-05-29